Anavex Life Sciences Corp (AVXL)

[Investor2014]

Yep, I overlooked the Source.

Thanks for the extra commentary on slide 19. However, we have to remember the switch in dosing between patients in the 1st and 2nd period (slide 7).

We don't know the profile (no KEM selection quite yet) of each patient and exactly how they may respond. Nevertheless, I think it may be expected that improvement initially accelerates and then improves more gradually for responders over time.